Navigation Links
Mass. Eye and Ear awarded largest NIH grant in hospital’s history
Date:9/6/2011

BOSTON (Sept. 6, 2011) The Massachusetts Eye and Ear Infirmary has received an $11 million grant from the National Institute of Allergy and Infectious Disease, the largest National Institutes of Health grant in this hospital's187-year history, to coordinate the Harvard-wide Project on Antibiotic Resistance.

The goal of the project, led by Dr. Michael S. Gilmore, Sir William Olser Professor of Ophthalmology, is to develop new antibiotics to treat highly resistant infections caused by staph and other related bacteria. Dr. Gilmore is a part of the Howe Laboratory of Ophthalmology at Mass. Eye and Ear.

"Infections from multidrug-resistant bacteria are leading complications of surgeries, from cataract extractions to knee replacements. Understanding how resistance develops in these strains will help guide the judicious and effective use of antibiotics, and the development of new treatments that will benefit patients and reduce health care spending," said Joan W. Miller, M.D., Henry Willard Williams Professor of Ophthalmology, Chief of Ophthalmology at Mass Eye and Ear and Mass General Hospital, and Chair of Ophthalmology at Harvard Medical School.

Since 2005, drug resistant Staphylococcus aureus has killed more people in the United States than HIV/AIDS, and it has become a leading public health concern. Because resistant staph infections are spread by hand-to-hand contact, workout facilities now provide hand sanitizers and routinely sanitize equipment. An outbreak of methicillin-resistant Staphylococcus aureus infection among the St. Louis Rams brought the problem into sharp public focus.

According to Dr. Gilmore, human beings all carry the bacterium Staphylococcus aureus somewhere on their bodies. They prefer moist areas and usually live in the nose, but also occur on the skin, in areas like armpits and groin, and elsewhere in and on the human body. Most of the time these microbes are just eking out a living and not doing any harm they may even be protecting us from something worse. However, to hold them in check, a body needs to be in good health. Turf burns, as in the case of the St. Louis Rams football team, surgery or hospitalization, and other diseases can tip the balance in favor of the microbe. Among hospitalized patients, staphylococcal infection is the largest infectious disease problem, and its prevention is a top concern.

Dr. Gilmore recruited a team of investigators from across the Harvard University landscape, and also from industry, to tackle the problem of developing new drugs to treat these infections. Massachusetts General Hospital scientists and physicians Drs. Eleftherios Mylonakis, Fred Ausubel, and David Hooper are pursuing new strategies for discovering and testing drugs using model systems. Harvard Medical School professors Drs. Suzanne Walker and Roberto Kolter are using high-throughput robotics to identify potential drugs that target the bacterial cell surface, and its organization. Dr. Kolter and Harvard Faculty of Arts and Science professor Dr. Richard Losick are exploring new approaches for disorganizing bacterial biofilms, making the microbes easier to treat with new and existing antibiotics. Dr. Keeta Gilmore is responsible for coordinating the moving parts, and for cultivating an atmosphere that promotes synergy between projects. This group converges twice monthly at the Mass. Eye and Ear to discuss progress and to coordinate activities.

According to Dr. Gilmore, early efforts stemming originally from the Walker lab and involving most of the collaborators have already turned up one promising lead compound that is in its second generation. He hopes the five-year project will generate between five and ten promising and tested new compounds for fighting multidrug-resistant infection caused by staph and related microbes including the highly challenging vancomycin-resistant Enterococcus. A group consisting of Drs. Jared Silverman (Cubist Pharmaceuticals, Inc.), Steve Projan (MedImmune, LLC), Chris T. Walsh (HMS), and Nathanael Grey (HMS), who are highly familiar with the process of moving new drugs from the bench to bedside, will be advising the Harvard-wide collaborative team.


'/>"/>
Contact: Mary Leach
Mary_Leach@meei.harvard.edu
617-573-4170
Massachusetts Eye and Ear Infirmary
Source:Eurekalert

Related biology news :

1. Mass. General researchers develop functional, transplantable rat liver grafts
2. Young investigators awarded for research excellence at Australia meeting
3. Wayne State start-up company NextCAT awarded nearly $500,000 from NSF for Phase II SBIR
4. Southampton researchers awarded $28 million to progress pioneering nutrition and respiratory research
5. BUSM professor awarded $13.3 million to study potential treatments to prevent STDs
6. Lincoln Park Zoo awarded 2 significant grants for science education
7. BUSM awarded $9 million to investigate treatment for sickle cell disease using iPS cells
8. Grants awarded to help bring promising bioscience discoveries to market
9. Johns Hopkins researchers awarded $32 million
10. UTMB-led researchers awarded $7.8 million for Gulf spill study
11. Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/16/2017)... -- CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog ... Used combined in one project, multi-biometric solutions provide ... ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology: